MedPath

SELVITA S A

🇵🇱Poland
Ownership
-
Employees
-
Market Cap
$299.7M
Website

Selvita Becomes First CRO to License Medicines Discovery Catapult's Patented Target Engagement Technology

Selvita has become the first contract research organization to license Medicines Discovery Catapult's Chemical Protein Stability Assay (CPSA), a patented technology designed to accelerate drug candidate identification and prioritization.

© Copyright 2025. All Rights Reserved by MedPath